This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nichols, H. B. Articles by Newcomb, P. A. Search for Related Content PubMed PubMed Citation Articles by Nichols, H. B. Articles by Newcomb, P. A.

Differences in Breast Cancer Risk Factors by Tumor Marker Subtypes among Premenopausal Vietnamese and Chinese Women

¹ University of Wisconsin Comprehensive Cancer Center and Departments of ² Population Health Sciences and ³ Medicine and Family Medicine, University of Wisconsin, Madison, Wisconsin; ⁴ Hospital K, Hanoi, Vietnam; ⁵ Breast Center at Baylor College of Medicine, Houston, Texas; and ⁶ Fred Hutchinson Cancer Research Center, Seattle, Washington

Requests for reprints: Hazel B. Nichols, University of Wisconsin Comprehensive Cancer Center, Madison, WI. Phone: 608-263-7890; Fax: 608-265-5330. E-mail: hbnichols{at}wisc.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
We evaluated associations between reproductive and lifestyle risk factors with breast cancer tumor marker status in a case-control study. Cases were premenopausal women living in Vietnam and China who were eligible for a clinical trial of oophorectomy and tamoxifen as treatment for breast cancer (n = 682). Controls were nonrelative hospital visitors, matched on age to the cases (n = 649). Immunohistochemical analysis was used to identify the presence of estrogen receptor (ER) and progesterone receptor and the overexpression of HER-2/neu oncogene. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using unconditional logistic regression, adjusted for known confounders. Overall, 280 (61%) tumor samples were ER positive and 176 (38%) were ER negative. HER-2/neu overexpression was detected in 161 (35%) samples, whereas 286 (26%) samples were HER-2/neu negative. We observed an inverse trend between increasing parity and decreasing breast cancer risk (P = 0.002). Women ages 25 years at first birth had increased breast cancer risk compared with women ages <25 years at first birth (OR, 1.53; 95% CI, 1.20-1.95). Women who consumed alcohol had increased risk of breast cancer compared with women who did not (OR,1.85; 95% CI, 1.32-2.61). Compared with controls, OR estimates for breast cancer by parity and age at first birth were significantly associated with ER and/or HER-2/neu tumor status by Wald test (P < 0.05). Family history, age at menarche, cumulative lactation, body mass index, and education were not significantly related to breast cancer risk. Our findings support the hypothesis that some breast cancer risk factors differ by ER and HER-2/neu tumor marker subtypes.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The effect of breast cancer can be measured on a global scale, with more than one million women diagnosed each year worldwide (1). An estimated 350,000 cases are premenopausal women living in Asia (2, 3). Few studies to date have evaluated breast cancer risk factors specifically in women in Southeast Asia (4-6). In addition to possible differences in risk factors from Western women, breast cancer in Southeast Asia may be characterized by a unique distribution of tumor marker subtypes. Studies in women from developed countries have identified several associations between tumor markers and reproductive factors (7-13).

Hormone receptors, such as the estrogen receptor (ER) and progesterone receptor (PR), are determinants of breast tumor behavior and may suggest etiologic pathways (14, 15). ERs bind estrogen and facilitate protein synthesis, cell division, and breast cell proliferation (16-18). PRs, in turn, are regulated by circulating levels of estrogen (16, 18). The presence of both estrogen and progesterone receptors in breast tumors has been associated with better survival and overall outcome (8, 19-22).

HER-2/neu, a proto-oncogene, is the most commonly amplified oncogene in human breast cancer (23). HER-2/neu and ER alterations occur early in breast carcinogenesis (14, 24). There is some evidence that HER-2/neu overexpression reflects distinct risk factor patterns, such as an association with early use of oral contraceptives (11, 13, 25). Tumors with HER-2/neu overexpression are characterized by poor prognosis and tend to be higher grade and hormone receptor negative (23).

Hormonal and dietary factors such as early age at menarche, late age at first birth, and alcohol consumption are established risk factors for breast cancer (26-28). We designed a case-control study to evaluate potential variation in these and other breast cancer risk factors by ER and HER-2/neu status among premenopausal Vietnamese and Chinese women.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Subject Identification
A randomized clinical trial of adjuvant surgical oophorectomy and tamoxifen was conducted at six hospitals in Vietnam and one hospital in China from 1993 to 1999 (29). Eligibility for participation in the clinical trial was determined by clinical and cytologic or pathologic evidence of operable breast cancer. Premenopausal women (defined as having had at least one menstrual period in the previous year) who had a new diagnosis of stage IIA, IIB, and IIIA breast tumors and a planned mastectomy within 10 weeks were eligible for enrollment. Additional inclusion criteria required a physical examination to confirm the absence of metastatic cancer and the presence of normal chest X-rays, liver function, and blood calcium levels within 10 weeks of study entry. Women with preoperative radiation remained eligible so long as pretreatment clinical staging fell within the categories described above. This study was evaluated and approved by institutional review boards at the University of Wisconsin Comprehensive Cancer Center, the Office for Protection of Research Risk of the U.S. NIH, the Scientific and Technical Council of the Ministry of Health in Vietnam, and institutional review committees in China. Trial conduct and results were periodically reviewed by an independent data monitoring committee. Further details concerning the clinical trial have been published elsewhere (29).

The case-control study was designed in conjunction with the ongoing clinical trial to investigate the association of reproductive and lifestyle risk factors and breast cancer tumor marker status among premenopausal Vietnamese and Chinese women. Enrollment for the clinical trial and case-control study was conducted simultaneously at Vietnamese hospitals in Hanoi and Ho Chi Minh City in 1993 and in Danang, Haiphong, Hue, and Nha Trang from 1995 to 1996. In 1997, enrollment was initiated at Haimen City Hospital in the Jiangsu Province of China. All women eligible for the clinical trial of oophorectomy and tamoxifen were eligible for the case-control study (n = 682). Control participants were female visitors to noncancer patients in participating hospitals, matched on single year of age to the cases (n = 649). All study participants gave written informed consent in Vietnamese or Chinese.

Data Collection
Structured in-person interviews were conducted by local staff to obtain information regarding reproductive experiences, menstrual history, family history of breast cancer, tea and alcohol consumption, and other lifestyle factors. Interview duration was 15 to 30 minutes.

Molecular Analysis
Breast cancer tumor samples from 458 cases (67%) were assessed for the presence of ER and PR proteins and overexpression of HER-2/neu proteins by immunocytochemistry 2 to 7 years after diagnosis. Immunohistochemical analysis of formalin-fixed, paraffin-embedded tissue samples was conducted according to previously validated methodology (30-33). These procedures and minor modifications are described in detail elsewhere (29, 34, 35).

Data Analysis
To evaluate the association of known risk factors and breast cancer among premenopausal women living in Vietnam and China we calculated odds ratios (OR) and 95% confidence intervals (95% CI) using unconditional logistic regression. Polytomous logistic regression models were created to analyze ER and HER-2/neu case status compared with all controls. Within polytomous models, associations between tumor subtypes were compared with the Wald test using variables parameterized both categorically and continuously. Final models were adjusted for age (5-year groups), parity (defined as the number of full term pregnancies lasting at least 6 months and resulting in a live or still birth, four categories), age at first full term pregnancy (5-year groups), alcohol use (beer or rice vodka, no/yes intake), spouse's education level (primary, middle, secondary, and college), and study site (five hospitals). Body mass index was calculated as weight (kg)/height (m)². To obtain Ps for trend, we included select variables as continuous linear terms in regression models. Analyses described above were done a second time after restricting the sample to women living in Vietnam only.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Our study population was composed of women living in Vietnam or China. Of the 682 case patients, 637 (93%) were women living in Vietnam and 45 (7%) were women living in China. Among the 649 controls, 609 (94%) were women living in Vietnam and 40 (6%) were women living in China. The mean age of case patients enrolled in the case-control study was 41 years (range, 24-57 years). Mean age among the controls was 42 years(range, 20-57 years).

Table 1 presents the distribution of reproductive risk factors between cases and controls. There was a significant trend between increases in parity and decreasing breast cancer risk (P = 0.002). We observed a significant trend between older ages at first full-term pregnancy and elevated breast cancer risk (P = 0.0007). Women who had their first full-term pregnancy at ages 25 years had 1.5 times the risk of developing breast cancer compared with women who had their first full-term pregnancy before age 25 (95% CI, 1.2-1.95). Family history (based on a diagnosis of breast cancer in a mother or sister), age at menarche, and total months of lactation were not significantly associated with breast cancer risk.

ER Status
ER status-specific ORs and 95% CIs are presented in Table 3. Parity was associated with a decrease in breast cancer risk in both ER-positive and ER-negative tumors. When evaluated continuously, parity was only associated with ER-positive tumors (P < 0.0001) but not ER-negative tumors (P = 0.6). The Wald test indicated that the ORs for parity (continuous) were significantly different (P < 0.01) for the ER subtypes. Late age at first full-term pregnancy was associated with increased breast cancer risk among ER-positive tumors (OR, 1.76; 95% CI, 1.29-2.42) and ER-negative tumors (OR, 1.49; 95% CI, 1.03-2.15), with both tumor subtypes exhibiting a positive trend between age at first full-term pregnancy as a continuous variable and breast cancer risk (P < 0.0001 and P = 0.01, respectively). A significant association between alcohol and breast cancer risk was observed in ER-positive tumors (OR, 1.75; 95% CI, 1.11-2.74) but not in ER-negative tumors (OR, 1.31; 95% CI, 0.75-2.28), although the direction of the association remained the same. Family history, age at menarche, lactation, body mass index, and education did not gain significance when evaluated based on tumor marker status.

HER-2/neu Overexpression
As shown in Table 4, the decreased risk of breast cancer observed among women with high parity was strongly associated with HER-2/neu-negative, compared with HER-2/neu-positive, tumors (P < 0.01 by Wald test). We observed an inverse trend between parity and HER-2/neu-negative breast cancer risk (P <0.0001); women with five or more births had 0.17 times the risk of HER-2/neu-negative breast cancer (95% CI, 0.07, 0.43) compared with nulliparous women. The increased risk among women with age at first full term pregnancy was also associated with HER-2/neu-negative tumors (P < 0.05 by Wald test). In this subtype, age at first full-term pregnancy 25 was associated with twice the risk of breast cancer (OR, 2.04; 95% CI, 1.49-2.80) with a positive trend between age at first full term pregnancy and breast cancer risk (P < 0.0001).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
We observed significant relationships between parity, age at first full-term pregnancy, and alcohol consumption with breast cancer risk among young and middle-aged Vietnamese and Chinese women.

The distributions of age at menarche and body mass index in our study were very different than those commonly observed in epidemiologic studies of Caucasian women. Similarly, within our study population, a very high percentage (93%) of women had breast-fed for a year or more cumulatively. The distributions of these risk factors are consistent with the relatively low incidence rates of breast cancer in Vietnam and China as compared with the United States (1).

Our study did not observe some of the known associations of breast cancer risk factors in the United States. For example, our results did not indicate significant associations with risk for family history, age at menarche, lactation history, or education level. As referenced above, the distribution of age at menarche and lactation history variables were unique to our study population of premenopausal Southeast Asian women; therefore, we would not necessarily expect to reproduce the associations between these factors and breast cancer risk observed in U.S. samples. Given that very few women reported breast cancer in close relatives, the frequency of major breast cancer genes (BRCA1 and BRCA2) in our study population was considered likely to be low relative to women of European descent. The lack of association between personal and/or spousal education level and breast cancer risk may indicate that these variables are not suitable proxies for socioeconomic status in Southeast Asia. Alternatively, patterns of risk may not fall along social class lines in Vietnam and China as they do in the United States (4-6). We are unable to disentangle the contributions of these risk factors from the putative underlying genetic predisposition of these premenopausal Asian women in relation to breast cancer risk.

Epidemiologic studies have repeatedly shown an increased risk of breast cancer associated with alcohol consumption (26, 27). Studies showing higher estrogen levels among women who consume alcohol have been cited as evidence of an operating biological mechanism (36, 37). Other mechanisms suggested include a direct carcinogenic effect of alcohol or its congeners on breast cancer risk (26, 27).

Within our study population of premenopausal women living in Vietnam and China, 61% of analyzed tumor samples were ER positive. This prevalence is similar to studies of young Caucasian women (7, 8, 19, 38). In a prospective investigation of postmenopausal American women, Sellers et al. (39) found that the increased risk of breast cancer associated with alcohol was limited to ER-negative tumors. Conversely, a case-control study of American women ages 20 to 79 years, conducted by Nasca et al. (40), found an association between ER-positive breast cancer and alcohol consumption and failed to detect any association with ER-negative tumors. In our polytomous regression models, the increased breast cancer risk associated with alcohol consumption did not differ significantly between ER-positive and ER-negative tumors.

Overexpression of the HER-2/neu protein has been identified in 10% to 34% of breast cancer cases in other studies (10, 41); in our study, 35% of cases had HER-2/neu-positive tumors. Tumors that overexpress HER-2/neu have been associated with the absence of hormone expression (10, 11, 42, 43). For this reason, it has been speculated that hormonal risk factors should only influence HER-2/neu-negative tumors (10, 42, 43).

An Italian study by Balsari et al. evaluated the risk associated with parity, age at menarche, and age at menopause by HER-2/neu status in two series of breast cancer patients in Milan (1st series: n = 1,211 patients and 2nd series: n = 717 patients). Their results were consistent with the hypothesis presented above; parity, age at menarche, and menopause were only associated with changes in breast cancer risk among HER-2/neu-negative cases but not HER-2/neu-positive cases (10). Our results lend support to this hypothesis in that we observed a relatively stronger association between parity and age at first birth on breast cancer risk among HER-2/neu-negative compared with HER-2/neu-positive tumors. However, unlike studies of women of Asian (44-46) and European (7, 12, 28) descent, we did not find an association between age at menarche and breast cancer risk, either overall or by tumor marker status.

Other investigations of HER-2/neu status and breast cancer risk factor associations have not been in agreement. Variation in the strength of associations by HER-2/neu status for reproductive risk factors is notable. In a large population-based case-control study in North Carolina, Huang et al. (9) observed similar associations for age at menarche, parity, and age at first birth between HER-2/neu-positive and HER-2/neu-negative tumors. An investigation in Sweden also failed to detect an association between HER-2/neu status and parity and age at first birth in their case-to-case analysis (25). However, Treurniet et al.'s (13) case-control analysis identified a 2- to 4-fold increase in both the protective effect of breast-feeding and the increased risk associated with late age at first full-term pregnancy among women with HER-2/neu-positive tumors.

Of note, when Huang et al. (9) adjusted their HER-2/neu results for ER status there was no change in the observed associations. However, Gammon et al. (11) found stark differences in ORs calculated from their case-control study of HER-2/neu and oral contraceptive use when they stratified by ER status. Among women with ER-positive breast tumors, the association between ever use of oral contraceptives and HER-2/neu-positive and HER-2/neu-negative breast cancer was null (11). However, among women with ER-negative tumors, ever use of oral contraceptives was significantly associated with HER-2/neu-positive breast cancer (OR, 2.58; 95% CI,1.31-5.10), but not HER-2/neu-negative breast cancer (OR, 0.92; 95% CI, 0.49-1.71; ref.11). Our study did not have sufficient sample size to investigate the possible interaction of ER and HER-2/neu status.

Biological evidence supports HER-2/neu and ER alterations early in breast carcinogenesis (14, 24). HER-2/neu protein is not found in benign breast tissue but may be present in all stages of malignant disease (47, 48). The hypothesis that hormone receptor and HER-2/neu overexpression are markers of etiologic heterogeneity has been supported by evidence of interaction between biomarkers and known risk factors for breast cancer in other epidemiologic studies (8, 11-13, 25, 49).

Several limitations should be considered in interpreting our study results. Due to inadequate record keeping, participation proportions for cases and controls are not available. Additionally, we were unable to complete immunohistochemical analysis on all cases. Of the 682 breast cancer patients enrolled in conjunction with the clinical trial of adjuvant surgical oophorectomy and tamoxifen, 224 case patients did not have assayable pathology samples. However, cases with samples and cases without samples were similar with respect to age, body mass index, education, and general risk factors of interest (data not shown) and are unlikely to introduce systematic bias. Immunohistochemistry offers a cost-efficient means of assessing tumor marker status for epidemiologic research; however, some misclassification of ER and/or HER-2/neu status may have occurred by this method (8, 11, 30, 32).

Our study relied upon self-reported data. As in all case-control studies, recall bias is a concern. In general, reproductive histories and lifestyle factors are validly and reliably recalled (50-52). However, there is little data on this issue in Asian epidemiologic studies. In the Shanghai Breast Self-Examination trial, women reliably reported abortion history in two interviews (53). The composition of our subject population may limit the generalizability of our findings. Cases were restricted to women with regionally advanced disease, so not all women with incident breast cancer were eligible for the parent clinical trial or this case-control study. The most appropriate control group for these cases is difficult to readily define. Our observed results may not apply to women diagnosed with stage I or stage IV breast cancer, postmenopausal women, or to women living in other countries with different genetic backgrounds.

Prior investigations have focused on the role of biomarker status in predicting tumor size, type, and grade, aggressiveness, lymph node status, recurrence, disease-free and overall survival, and treatment response (16, 18, 20-23, 49). The primary strength of our study is our ability to provide much-needed information on the differential relation between reproductive and lifestyle risk factors and breast cancer risk by two highly prevalent tumor markers. In our study, the potential for confounding by ethnicity, menopausal status and cancer stage was extremely limited.

This study of women living in Vietnam and China suggests that reproductive patterns and emerging lifestyle behaviors such as alcohol consumption are strongly associated with premenopausal breast cancer risk. Interactions between reproductive factors with breast cancer tumor markers may suggest differences in etiologic pathways.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be here by marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2/ 6/04; revised 7/29/04; accepted 8/ 6/04.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC CancerBase. Lyon: IARC Press; 2001.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.[Abstract/Free Full Text]
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.[CrossRef][Medline]
4. Quoc NM, Hung NC, Parkin DM. Cancer incidence in Ho Chi Minh City, Viet Nam, 1995-1996. Int J Cancer 1998;76:472-9.[CrossRef][Medline]
5. Petralia SA, Chow WH, McLaughlin J, Jin F, Gao YT, Dosemeci M. Occupational risk factors for breast cancer among women in Shanghai. Am J Ind Med 1998;34:477-83.[CrossRef][Medline]
6. Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987-1999. Int J Cancer 2003;106:771-83.[CrossRef][Medline]
7. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.[Abstract/Free Full Text]
8. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151:703-14.[Abstract/Free Full Text]
9. Huang WY, Newman B, Millikan RC, et al. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev 2000;9:65-71.[Abstract/Free Full Text]
10. Balsari A, Casalini P, Bufalino R, Berrino F, Menard S. Role of hormonal risk factors in HER2-positive breast carcinomas. Br J Cancer 2003;88:1032-4.[CrossRef][Medline]
11. Gammon MD, Hibshoosh H, Terry MB, et al. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999;8:413-9.[Abstract/Free Full Text]
12. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995;4:319-26.[Abstract]
13. Treurniet HF, Rookus MA, Peterse HL, Hart AA, van Leeuwen FE. Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor. Cancer Res 1992;52:2344-5.[Abstract/Free Full Text]
14. Elledge RM, Fuqua SAW. Estrogen and progesterone receptors. In: JR Harris, et al. editors. Diseases of the breast. Philadelphia: Lippincott-Williams & Wilkins; 2000. p. 471–88.
15. Sellers TA, Davis J, Cerhan JR, et al. Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Am J Epidemiol 2002;155:225-33.[Abstract/Free Full Text]
16. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer 1984;53:630-43.[CrossRef][Medline]
17. King WJ, Greene GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 1984;307:745-7.[CrossRef][Medline]
18. Rayter Z. Steroid receptors in breast cancer. Br J Surg 1991;78:528-35.[Medline]
19. Enger SM, Ross RK, Paganini-Hill A, Carpenter CL, Bernstein L. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomarkers Prev 2000;9:681-7.[Abstract/Free Full Text]
20. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992;326:1756-61.[Medline]
21. Clahsen PC, van de Velde CJ, Duval C, et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 1999;25:356-63.[CrossRef][Medline]
22. Mauri FA, Maisonneuve P, Caffo O, et al. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up. Int J Oncol 1999;15:1137-47.[Medline]
23. Van de Vijver MJ, Nusse R. The molecular biology of breast cancer. Biochim Biophys Acta 1991;1072:33-50.[Medline]
24. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-32.[Medline]
25. Olsson H, Borg A, Ferno M, Ranstam J, Sigurdsson H. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst 1991;83:1483-7.[Abstract/Free Full Text]
26. Singletary K, Gapstur S. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001;286:2143-51.[Abstract/Free Full Text]
27. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998;279:535-40.[Abstract/Free Full Text]
28. Ketcham AS, Sindelar WF. Risk factors in breast cancer. Prog Clin Cancer 1975;6:99-114.[Medline]
29. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20:2559-66.[Abstract/Free Full Text]
30. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.[Abstract/Free Full Text]
31. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.[Medline]
32. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998;4:7-12.[Abstract]
33. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-63.[Abstract/Free Full Text]
34. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860-4.
35. Love RR, Duc NB, Havighurst TC, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21:453-7.[Abstract/Free Full Text]
36. Reichman ME, Judd JT, Longcope C, et al. Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women. J Natl Cancer Inst 1993;85:722-7.[Abstract/Free Full Text]
37. Muti P, Trevisan M, Micheli A, et al. Alcohol consumption and total estradiol in premenopausal women. Cancer Epidemiol Biomarkers Prev 1998;7:189-93.[Abstract]
38. Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 1999;10:431-7.[CrossRef][Medline]
39. Sellers T, Vierkant R, Cerhan J, et al. Interaction of dietary folate intake, alcohol, and risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Cancer Epidemiology Biomarkers Prev 2002;11:1104-7.[Abstract/Free Full Text]
40. Nasca PC, Liu S, Baptiste MS, Kwon CS, Jacobson H, Metzger BB. Alcohol consumption and breast cancer: estrogen receptor status and histology. Am J Epidemiol 1994;140:980-8.[Abstract/Free Full Text]
41. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237-52.[Abstract/Free Full Text]
42. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.[Medline]
43. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.[Abstract/Free Full Text]
44. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000;87:295-300.[CrossRef][Medline]
45. Yuan JM, Yu MC, Ross RK, Gao YT, Henderson BE. Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res 1988;48:1949-53.[Abstract/Free Full Text]
46. Wang QS, Yu MC, Henderson BE. Risk factors for breast cancer in Tianjin, People's Republic of China. Natl Cancer Inst Monogr 1985;69:39-42.
47. Regidor PA, Callies R, Schindler AE. Level of c-erbB-2 oncoprotein in the homogenate of malignant and benign breast tumor samples. Eur J Gynaecol Oncol 1995;16:130-7.[Medline]
48. Brower ST, Tartter PI, Ahmed S, et al. Proliferative indices and oncoprotein expression in benign and malignant breast biopsies. Ann Surg Oncol 1995;2:416-23.[Abstract]
49. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 2001;19:18-27.[Abstract/Free Full Text]
50. Longnecker MP, Newcomb PA, Mittendorf R, et al. The reliability of self-reported alcohol consumption in the remote past. Epidemiology 1992;3:535-9.[Medline]
51. Trentham-Dietz A, Newcomb PA, Storer BE, et al. Body size and risk of breast cancer. Am J Epidemiol 1997;145:1011-9.[Abstract/Free Full Text]
52. Egan KM, Stampfer MJ, Rosner BA, et al. Risk factors for breast cancer in women with a breast cancer family history. Cancer Epidemiol Biomarkers Prev 1998;7:359-64.[Abstract]
53. Ye Z, Gao DL, Qin Q, Ray RM, Thomas DB. Breast cancer in relation to induced abortions in a cohort of Chinese women. Br J Cancer 2002;87:977-81.[CrossRef][Medline]

This article has been cited by other articles:

				A. Bardia, L. C. Hartmann, C. M. Vachon, R. A. Vierkant, A. H. Wang, J. E. Olson, T. A. Sellers, and J. R. Cerhan Recreational Physical Activity and Risk of Postmenopausal Breast Cancer Based on Hormone Receptor Status Arch Intern Med, December 11, 2006; 166(22): 2478 - 2483. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nichols, H. B. Articles by Newcomb, P. A. Search for Related Content PubMed PubMed Citation Articles by Nichols, H. B. Articles by Newcomb, P. A.